The role of miR-21, miR-29c and miR-182 in pleural effusion in differentiating benign and malignant origin
YUAN Rong-Xia1, LI Jian1, JIN Jun2, WANG Yi2
（1. Department of Respiratory Medicine, 2. Center of Medical Experiment, the Affiliated Hospital of Jiangsu University, Zhenjiang Jiangsu 212001, China)
Abstract：Objective: To evaluate the diagnostic utility of miR21, miR29c and miR182 expressions in pleural effusion in differentiating benign and malignant origin. Methods: The expression of miR21, miR29c and miR182 in pleural effusion specimens from 65 patients with malignant pleural effusion and 61 patients with benign pleural effusion were detected by fluorescence quantitative PCR. The differences of the three miRNA levels between benign and malignant pleural effusions were compared. The receiver operating characteristic (ROC) curves were established, in which the area under the ROC curves (AUCs) were calculated. According to the optimal cutoff points defined by analyzing ROC curves, sensitivity, specificity and other indices were calculated. The diagnostic value of the three miRNAs for malignant pleural effusion was compared with a classical tumor marker, carcinoembryonic antigen(CEA). Results: The expression levels of miR21 and miR182 in malignant pleural effusion were markedly elevated compared with those in benign pleural effusion(P<0.05), while the expression level of miR29c was notably declined compared to that of benign pleural effusion(P<0.05). The ROC curve analyses showed that the AUCs of miR21, miR29c and miR182 for differentiating malignant from benign pleural effusion were 0.873 (95%CI, 0.808-0.939), 0.856 (95%CI, 0.790-0.920) and 0.841 (95%CI, 0.772-0.911) respectively, which was higher than that of CEA (0.822,95% CI, 0.703-0.873). The sensitivity of miR21, miR29c and miR182 in the diagnosis of malignant pleural effusion were 83.1%, 78.5% and 83.1% respectively, and the specificity was 85.2%, 81.5% and 73.4% respectively, which was higher than those of CEA. The sensitivity(93.8%) and specificity(90.2%) for diagnosing malignant pleural effusion were raised by combination of the three microRNAs and CEA. Conclusion: miR21, miR29c and miR182 may be candidate biomarkers in diagnosis of malignant pleural effusions.
袁荣霞1， 李坚1， 金君2， 汪毅2. miR-21、miR-29c和miR-182鉴别诊断良恶性胸腔积液[J]. 江苏大学学报:医学版, 2018, 28(02): 158-162,168.
YUAN Rong-Xia1, LI Jian1, JIN Jun2, WANG Yi2. The role of miR-21, miR-29c and miR-182 in pleural effusion in differentiating benign and malignant origin. Journal of Jiangsu University(Medicine Edition), 2018, 28(02): 158-162,168.
［1］Hsieh WY, Kuan TC, Cheng KS, et al. ACE/ACE2 ratio and MMP9 activity as potential biomarkers in tuberculous pleural effusions\[J\]. Int J Biol Sci, 2012, 8(8): 1197-1205.［2］Ried M, Hofmann HS. The treatment of pleural carcinosis with malignant pleural effusion\[J\]. Dtsch Arztebl Int, 2013, 110(18):313-318.［3］Tang Y, Xu L. Superiority and clinical significance of Lunx mRNA in the diagnosis of malignant pleural effusion caused by pulmonary carcinoma\[J\]. J Exp Clin Cancer Res, 2013, 32(1):37.［4］Agrawal A, Tandon R, Singh L, et al. Clinico pathological profile and course of malignant pleural effusion in a tertiary care teaching hospital in western U.P. with special reference to lung cancer\[J\]. Lung India, 2015, 32(4):326-330.［5］Sriram KB, Relan V, Clarke BE, et al. Pleural fluid cellfree DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas\[J\]. BMC Cancer, 2012, 12:428.［6］Penz E, Watt KN, Hergott CA, et al. Management of malignant pleural effusion: challenges and solutions\[J\]. Cancer Manag Res, 2017, 9:229-241.［7］Antonangelo L, Sales RK, Cor AP, et al. Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results\[J\]. Curr Oncol, 2015, 22(5): e336-341.［8］Hooper C, Lee YC, Maskell N, et al. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010\[J\]. Thorax, 2010, 65（Suppl 2):ii4-ii17.［9］Shojaee S, Lee HJ. Thoracoscopy: medical versus surgicalin the management of pleural diseases\[J\]. J Thorac Dis, 2015, 7(Suppl 4):S339-S351.［10］Psatha A, Makris D, Kerenidi T, et al. A Potential role for VEGF in the diagnostic approach of pleural effusions\[J\]. J Thorac Dis, 2016, 8(7):1681-1687.［11］Lee SH, Park MJ, Choi SI, et al. Reactive oxygen species modulator 1 (Romo1) as a novel diagnostic marker for lung cancerrelated malignant effusion\[J\]. Medicine (Baltimore), 2017, 96(4): e5975.［12］Cortez MA, BuesoRamos C, Ferdin J, et al. MicroRNAs in body fluids—the mix of hormones and biomarkers\[J\]. Nat Rev Clin Oncol, 2011, 8(8):467-477.［13］Wang B, Zhang Q. The expression and clinical significance of circulating microRNA21 in serum of five solid tumors\[J\]. J Cancer Res Clin Oncol, 2012, 138(10): 1659-1666.［14］Guan P, Yin Z, Li X, et al. Metaanalysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues\[J\]. J Exp Clin Cancer Res, 2012, 31(1):54.［15］Corcoran C, Friel AM, Duffy MJ, et al. Intracellular and extracellular microRNAs in breast cancer\[J\]. Clin Chem, 2011, 57(1): 18-32.［16］Pass HI, Goparaju C, Ivanov S, et al. hsamiR29c* is linked to the prognosis of malignant pleural mesothelioma\[J\]. Cancer Res, 2010, 70(5):1916-1924.［17］Han TS, Hur K, Xu G, et al. MicroRNA29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1\[J\]. Gut, 2015, 64(2):203-214.［18］Zhang QH, Sun HM, Zheng RZ, et al. Metaanalysis of microRNA183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues\[J\]. Gene, 2013, 527(1):26-32.［19］Qin X, Xu H, Gong W, et al. The tumor cytosol miRNAs, fluid miRNAs, and exosome miRNAs in lung cancer\[J\]. Front Oncol, 2015, 4: 357.［20］Erbes T, Hirschfeld M, Rücker G, et al. Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative noninvasive biomarker\[J\]. BMC Cancer, 2015, 15:193.［21］Geng Q, Fan T, Zhang B, et al. Five microRNAs in plasma as novel biomarkers for screening of earlystage nonsmall cell lung cancer\[J\]. Respir Res， 2014, 15(1):149.［22］Frezzetti D, De Menna M, Zoppoli P, et al. Upregulation of miR21 by Ras in vivo and its role in tumor growth\[J\]. Oncogene, 2011, 30(3): 275-286.［23］Le HB, Zhu WY, Chen DD, et al. Evaluation of dynamic change of serum miR21 and miR24 in pre and postoperative lung carcinoma patients\[J\]. Med Oncol, 2012, 29(5): 3190-3197.［24］Wei J, Gao W, Zhu CJ, et al. Identification of plasma microRNA21 as a biomarker for early detection and chemosensitivity of nonsmall cell lung cancer\[J\]. Chin J Cancer, 2011, 30(6): 407-414.［25］Yu J, Lei R, Zhuang X, et al. MicroRNA182 targets SMAD7 to potentiate TGFβinduced epithelialmesenchymal transition and metastasis of cancer cells\[J\]. Nat Commun, 2016, 7: 13884.［26］Wang X, Wang R, Li F, et al. Relationship between miR21 and miR182 levels in peripheral blood and gastric cancer tissue\[J\]. Oncol Lett, 2017, 14(2): 1427-1432.［27］李威, 陈燕明, 陈晓军,等. 胸腔积液中miRNA21和miRNA155表达的诊断价值\[J\]. 江苏医药, 2012,38(16):1882-1884.［28］Chen G, Zhou T, Li Y, et al. p53 target miR29c3p suppresses colon cancer cell invasion and migration through inhibition of PHLDB2\[J\]. Biochem Biophys Res Commun, 2017， 487(1):90-95.［29］Xu H, Yao Y, Meng F, et al. Predictive value of serum miR10b, miR29c, and miR205 as promising biomarkers in esophageal squamous cell carcinoma screening\[J\]. Medicine(Baltimore), 2015, 94 (44):e1558.［30］Zhu W,He J,Chen D, et al. Expression of miR29c,miR93, and miR429 as potential biomarkers for detection of early stage nonsmall lung cancer\[J\]. PLoS One, 2014, 9(2):e87780.［31］Zhu WY, Zhou K, Zha Y, et al. Diagnostic value of serum miR182, miR183, miR210, and miR126 levels in patients with earlystage nonsmall cell lung cancer\[J\]. PLoS One, 2016, 11(4):e0153046.
2018, Vol. 28 
